Compare Mesoblast Limited (MESO) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $57.11. The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | SPUS | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $20.96 | $59.51 |
52-Week Low | $12.88 | $45.32 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
SPUS trades at $56.32, down 0.23% on the day, with a neutral technical signal overall. The stock shows bullish moving average alignment but oscillators indicate indecision. Recent dividends of $0.03 per share were distributed in April, May, and June 2026, reflecting a stable income component. Key support lies at $56, with resistance near $57.
Outlook remains balanced; dividend consistency supports income investors, but limited fundamental data and neutral technicals suggest cautious optimism. Risks include market volatility and reliance on broader dividend strategy performance. Upside depends on sustained dividend growth and favorable market conditions for income-focused equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
